VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model

VelaVigo Cayman Limited Denmark Finland Germany Netherlands Sweden United Kingdom China Massachusetts

View original content:https://www.prnewswire.co.uk/news-releases/velavigo-announces-second-out-licensing-deal-of-a-first-in-class-bi-specific-antibody-further-validating-its-innovative-discovery-platform-and-sustainable-bdvc-business-model-302431724.html